|
Abciximab
resources
|
|
|
|
|
|
DRUG INFO
Abciximab
Drug Name:
Abciximab
Indication: For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina
Pharmacology: Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.
Mechanism Of Action: Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa.
Drug Category: Anticoagulants; Antiplatelet Agents
Brand Names/Synonyms: ReoPro; 7E3 antibody; antiGPIIBIIIa; ReoPro (Centocor)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Chimeric human-murine (anti CD41) 7E3 antibody.
Chemical Formula: C6462H9964N1690O2049S48 >1TXV:L ReoPro-like antibody Light Chain 1 >1TXV:H ReoPro-like antibody Heavy Chain 2 >1TXV:L ReoPro-like antibody Light Chain 2
Half Life: <10 min-30 min
Drug Type: Approved Drug
# Accession No: BIOD00041
CAS Registry Number: 143653-53-6
|
|
|
|
|
|
Abciximab News
(When available)
Angioplasty Saves the Day After Failed Thrombolysis for MI Dec 28, 2005
MedPage Today, 505). In this group, 68.5% of patients received stents, and 43.4% received the glycoprotein IIb/IIIa receptor inhibitor abciximab. ...
Colleges seek to make scientific research pay off Dec 19, 2005
MSNBC ReoPro is a drug administered to angioplasty patients to prevent blood clotting and Periostat is a rinse used to treat periodontal disease. ...
Get your arteries unclogged in a flash Dec 19, 2005
Salem Statesman Journal, The study was funded by Eli Lilly and Co., Bristol-Myers Squibb and Sanofi-Aventis, makers of ReoPro, the anti-clotting drug used in the experiment. ...
More flow for antithrombotics Dec 30, 2005
Med Ad News (subscription), ...market are Plavix, Lovenox, Otsuka America Pharmaceutical Inc.’s Pletal, Sanofi-Aventis’ fraxiparine, Coumadin, and Eli Lilly and Co.’s ReoPro...
|
|
|
